CELC (Celcuity) GF Value : $0.00 (As of Apr. 04, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Celcuity GF Value?

As of today (2025-04-04), Celcuity's share price is $7.96. Celcuity's GF Value is $0.00. Therefore, Celcuity's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Celcuity is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Celcuity (NAS:CELC) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Celcuity's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	7.96	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity GF Value Related Terms

Thank you for viewing the detailed overview of Celcuity's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Celcuity Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446

Website

https://www.celcuity.com

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Executives

Richard E Buller	director	C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey	director	C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht	director	C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan	director, 10 percent owner, officer: Chief Executive Officer	16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon	director	CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing	director, 10 percent owner, officer: Chief Science Officer, VP	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne	officer: Chief Financial Officer	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin	director	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446